SABS
SAB Biotherapeutics·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 1
Consensus Rating "Strong Buy"
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SABS
Sab Biotherapeutics, Inc.
A clinical-stage biopharmaceutical company engages in advancing immunotherapies leveraging human polyclonal antibodies
777 W 41st St, Miami Beach, Florida 33140
--
SAB Biotherapeutics, Inc., was incorporated in Delaware on November 12, 2020. The company is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapy antibodies (human immunoglobulin G, HIGG) for the treatment of immunological disorders. The company's pipeline projects have achieved proof-of-concept in clinical trials for indications with significant unmet medical needs, and product candidates target diseases including type 1 diabetes (T1D) and other autoimmune diseases. The antibodies found inside are both target-specific and polyclonal. They are composed of multiple HIGGs and can bind to multiple sites on targeted immunogens, making them ideal for solving complex immune-mediated diseases. The company's proprietary platform can generate more new therapeutic candidates to expand its pipeline, leveraging the human immune response to generate the best library of HIGG for drug targets of interest.
Company Financials
EPS
SABS has released its 2025 Q3 earnings. EPS was reported at -0.21, versus the expected -0.12, missing expectations. The chart below visualizes how SABS has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
